Pharmacology of a new antianginal drug: perhexiline. I. Coronary circulation and myocardial metabolism.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Y W Cho.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The intravenous infusion of cetiedil to a group of ten male volunteers elicited atropine-like side effects on salivation, bronchomotor tone and visual accommodation. With repeated infusions of cetiedil, the incidence as well as the duration of the side effects were reduced significantly, indicating the development of tolerance. Since normal subjects can tolerate repeated intravenous infusions of cetiedil, the clinical investigation of this drug in sickle cell disease can proceed, including those patients suffering from vasoocclusive crises.
Explore the source record for details and available documents.